Product
JNJ-64281802
Aliases
JNJ-64281802 Dosing Regimen X, JNJ-64281802 Dosing Regimen Y, JNJ-64281802 Dosing Regimen Z, JNJ-64281802 High dose (2 other aliases)
5 clinical trials
2 indications
Indication
DengueIndication
HealthyClinical trial
A Phase 2a, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Antiviral Activity, Safety and Tolerability, and Pharmacokinetics of JNJ-64281802 in Participants With Confirmed Dengue FeverStatus: Terminated, Estimated PCD: 2022-09-24
Clinical trial
A Phase 2a, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics of Repeated Oral Doses of JNJ-64281802 Against Dengue Serotype 1 Infection in a Dengue Human Challenge Model in Healthy Adult ParticipantsStatus: , Estimated PCD: 2024-01-31
Clinical trial
A Phase 1, Open-Label Study in Healthy Adult Participants to Assess the Pharmacokinetics of JNJ-64281802 Administered as Different Multiple Dose RegimensStatus: Completed, Estimated PCD: 2022-12-11
Clinical trial
A Phase 2, Randomized, Double-blind, Placebo-controlled, Double-dummy, Multicenter Trial Assessing the Efficacy and Safety of Two Dose Regimens of JNJ-64281802 for the Prevention of Dengue InfectionStatus: Recruiting, Estimated PCD: 2025-05-22
Clinical trial
A Phase 2a, Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics of Repeated Oral Doses of JNJ-64281802 Against Dengue Serotype 3 Infection in a Dengue Human Challenge Model in Healthy Adult ParticipantsStatus: Recruiting, Estimated PCD: 2023-05-16